Loading…
Loading…
would that imply a bit of a slowdown that you are starting the year at for consumables
Could you just unpack a little bit on the pharma piece? What you are seeing in life sciences
Life Science is probably, I guess, 0. Could you unpack a little bit
it's hard for us to parse what's really incremental, what's just shifting from one region to the other
I think you talked about the seventh consecutive quarter of a book to bill that was solidly over one
Could you just speak to kind of know, what's baked in for the 2025 guide, how we think about that low double digits continuing
any activity from the government in -- kind of reaction to the tariff wars
the full year guide would imply a nice step-up in the back half of the year. So just can you walk through some of the visibility
how do we think about the impact of Danaher's kind of your overall growth from these patent expirations
Can you just remind us, Rainer, of the linkage between orders and the forward growth for your Bioprocess business
is that just conservatism or maybe you were out punching the market in 2025
you want investors to like, 3% start at 3% for 2026 and around 1% the first quarter for organic. Is that right
Anyway, just help frame sizing magnitude or just any way to kind of contemplate what this can mean for Thermo Fisher
how much ultimately kind of the tariff changes occurred and kind of what's happening in 4Q
what type of maybe pharma R&D growth or other kind of factors you would kind of be using in order to support that 4% growth